# PsA Secukinumab XCT Structural Progression Study

> **NCT03623867** · PHASE4 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 40 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03623867
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-18
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623867, "PsA Secukinumab XCT Structural Progression Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03623867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*